ACTR087

BIOLOGICAL2 trials

Sponsors

Cogent Biosciences, Inc.

Conditions

LymphomaMultiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma

Phase 1

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

CompletedNCT02776813

Cogent Biosciences, Inc.Lymphoma

Start: 2016-08-31End: 2020-02-12Updated: 2020-03-31

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

TerminatedNCT03266692

Cogent Biosciences, Inc.Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma

Start: 2018-02-22End: 2019-10-01Updated: 2020-03-30

Related Papers

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.

2020-04-2977 citations

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Blood2019-11-1314 citations

Abstract OT2-07-06: Antibody-coupled T cell receptor (ACTR) engineered autologous T cells in combination with trastuzumab for the treatment of HER2-positive malignancies

Cancer Research2019-02-15

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Blood2018-11-296 citations

Abstract B105: ACTR707: a novel T-cell therapy for the treatment of relapsed or refractory CD20+ B cell lymphoma in combination with rituximab

Molecular Cancer Therapeutics2018-01-013 citations

Abstract A163: Effective targeting of HER2-amplified cancers with trastuzumab in combination with T cells expressing a novel Antibody-Coupled T-cell Receptor (ACTR)

Molecular Cancer Therapeutics2018-01-01

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Blood2017-12-073 citations

A First-in-Human Study of Autologous T Lymphocytes with Antibody-Dependent Cell Cytotoxicity (ADCC) in Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

Blood2016-12-024 citations

Targeting CD20+ Relapsed Refractory B Cell Lymphoma with ACTR087, Antibody-Coupled T-Cell Receptor (ACTR) Engineered Autologous T Cells, in Combination with Rituximab

Blood2016-12-022 citations